Literature DB >> 15539139

Intrabodies: production and promise.

Martin R Stocks1.   

Abstract

Antibodies are among the most powerful tools in biological research and are presently the fastest growing category of new drug entities. It has long been a dream to harness their power to probe and modulate activities inside living cells. The binding of an antibody to an intracellular molecule has the potential to block, suppress, alter or even enhance the process mediated by that molecule. In particular, intracellular use of antibody fragments can offer an effective alternative to gene-based knockout technologies, potentially with more control and subtlety of outcome. This article outlines progress in the development of intracellular antibodies or intrabodies and highlights their potential, both as drug-discovery tools and as drug entities in their own right.

Mesh:

Substances:

Year:  2004        PMID: 15539139     DOI: 10.1016/S1359-6446(04)03269-6

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  7 in total

Review 1.  Targeting antibodies to the cytoplasm.

Authors:  Andrea L J Marschall; André Frenzel; Thomas Schirrmann; Manuela Schüngel; Stefan Dübel
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

2.  Monitoring cotranslational protein folding in mammalian cells at codon resolution.

Authors:  Yan Han; Alexandre David; Botao Liu; Javier G Magadán; Jack R Bennink; Jonathan W Yewdell; Shu-Bing Qian
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-16       Impact factor: 11.205

3.  Delivery of antibodies to the cytosol: debunking the myths.

Authors:  Andrea L J Marschall; Congcong Zhang; André Frenzel; Thomas Schirrmann; Michael Hust; Franck Perez; Stefan Dübel
Journal:  MAbs       Date:  2014-05-21       Impact factor: 5.857

4.  From bench to bedside: the growing use of translational research in cancer medicine.

Authors:  Erin M Goldblatt; Wen-Hwa Lee
Journal:  Am J Transl Res       Date:  2010-01-01       Impact factor: 4.060

5.  beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide.

Authors:  Paolo Paganetti; Verena Calanca; Carmela Galli; Muriel Stefani; Maurizio Molinari
Journal:  J Cell Biol       Date:  2005-03-14       Impact factor: 10.539

6.  Selective blockade of trypanosomatid protein synthesis by a recombinant antibody anti-Trypanosoma cruzi P2β protein.

Authors:  Maximiliano Juri Ayub; Benson Nyambega; Leandro Simonetti; Tomas Duffy; Silvia A Longhi; Karina A Gómez; Johan Hoebeke; Mariano J Levin; Cristian R Smulski
Journal:  PLoS One       Date:  2012-05-03       Impact factor: 3.240

7.  Generation of functional scFv intrabody to abate the expression of CD147 surface molecule of 293A cells.

Authors:  Khajornsak Tragoolpua; Nutjeera Intasai; Watchara Kasinrerk; Sabine Mai; Yuan Yuan; Chatchai Tayapiwatana
Journal:  BMC Biotechnol       Date:  2008-01-29       Impact factor: 2.563

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.